Medscape's 2026 Canada physician compensation report shows average total physician compensation of C$394,000, while fewer than half of respondents say they feel fairly paid. Average base salary was reported at C$290,000, with the survey also highlighting unpaid work and continuing financial pressure across the Canadian medical workforce. The findings provide a current benchmark for physician earnings, perceived compensation fairness and the wider economics affecting medical practice in Canada. Field Content Article Type Compensation Report Medscape Canada Physician Compensation Report 2026 Geography Canada Average Total Compensation C$394,000 Average Base Salary C$290,000 Fairly Compensated 47% of respondents Topic Physician compensation and workforce economics What Happened Medscape published its 2026 Canadian physician compensation report with new data on earnings and perceptions of pay. Why It Matters The report provides a current benchmark for physician remuneration while highlighting ongoing dissatisfaction with compensation and the burden of unpaid work. Supporting Context Less than half of surveyed physicians said they felt fairly compensated despite average total compensation approaching C$400,000. Workforce Context The findings sit within broader concerns around physician workload, practice costs and recruitment and retention pressures. Potential Impact Compensation trends can influence specialty choice, workforce mobility, recruitment and long-term health-system staffing. Key Takeaway Canadian physicians reported average total compensation of C$394,000, but only 47% said they felt fairly compensated. What to Watch Specialty-level pay differences, gender gaps, changes in unpaid workload and future compensation trends. Primary Source Medscape Relevant Date 29 September 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

Novo Nordisk has licensed Hengrui Pharma's once-weekly oral GLP-1/GIP dual receptor agonist HRS-1596 in a global deal worth up to $2.6 billion. Hengrui will receive $300 million upfront, while Novo Nordisk gains exclusive rights outside Greater China to the Phase I-ready metabolic-disease candidate. The agreement adds another oral incretin programme to Novo Nordisk's pipeline as competition intensifies across obesity and diabetes treatment. Field Content Article Type Deals Companies Novo Nordisk; Hengrui Pharma Deal Type Exclusive global licensing agreement Asset HRS-1596 Therapy Areas Obesity; type 2 diabetes; metabolic disease Technology/Modality Once-weekly oral GLP-1/GIP dual receptor agonist Development Stage Phase I-ready Upfront Payment $300 million Potential Deal Value Up to $2.6 billion Additional Economics Sales royalties Geography Worldwide excluding Greater China What Happened Novo Nordisk secured exclusive rights outside Greater China to Hengrui Pharma's HRS-1596. Why It Matters The transaction adds a once-weekly oral incretin candidate to Novo Nordisk's metabolic pipeline as competition grows around more convenient obesity and diabetes therapies. Supporting Context HRS-1596 is designed as an oral dual agonist of the GLP-1 and GIP receptors. Strategic Rationale Novo Nordisk gains another potential oral metabolic therapy while Hengrui receives substantial upfront funding and downstream milestone opportunities. Potential Impact Successful development could broaden treatment choice beyond injectable incretin medicines. Key Takeaway Novo Nordisk has licensed HRS-1596 in a deal worth up to $2.6 billion, including $300 million upfront. What to Watch Entry into clinical development, early safety and efficacy data and future positioning within Novo Nordisk's obesity and diabetes portfolio. Primary Source Novo Nordisk / Hengrui Pharma Relevant Date 29 September 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

ALK is investing approximately DKK 500 million to expand its long-term manufacturing partnership with Catalent and increase capacity for fast-dissolving allergy immunotherapy tablets. The three-year investment programme is expected to add around 300 million tablets of annual capacity, taking potential production to approximately 1.1 billion tablets from the early 2030s. The expanded partnership also secures long-term access to Catalent's Zydis technology and could support future peanut and tree-nut allergy tablet programmes. Field Content Article Type Deals Companies ALK; Catalent Deal Type Strategic manufacturing partnership expansion Investment Approximately DKK 500 million over three years Technology/Platform Catalent Zydis fast-dissolving tablet technology Therapy Areas Allergy; immunotherapy Manufacturing Scope Allergy immunotherapy tablets Additional Annual Capacity Approximately 300 million tablets Expected Total Annual Capacity Approximately 1.1 billion tablets from the early 2030s Potential Future Programmes Peanut and tree-nut allergy tablets What Happened ALK expanded its manufacturing partnership with Catalent through a DKK 500 million investment programme. Why It Matters The agreement materially increases production capacity for ALK's tablet-based allergy immunotherapy portfolio and secures long-term access to a specialised drug-delivery platform. Supporting Context Catalent's Zydis technology is used for rapidly dissolving oral tablets and forms part of ALK's existing allergy tablet manufacturing network. Strategic Rationale ALK is expanding capacity ahead of anticipated long-term demand and potential launches in additional allergy indications. Potential Impact Higher capacity could support wider global access to allergy immunotherapy tablets and future expansion into food-allergy treatment. Key Takeaway ALK is committing around DKK 500 million to increase annual allergy-tablet capacity to approximately 1.1 billion units. What to Watch Capacity build-out, future product launches and development of peanut and tree-nut allergy tablets. Primary Source ALK Relevant Date 30 September 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

The FDA has approved Gazyva for patients aged two years and older with frequently relapsing or steroid-dependent childhood-onset idiopathic nephrotic syndrome who are in complete remission. Gazyva (obinutuzumab) reduced relapse risk in the Phase III INShore study, with 95% of treated patients experiencing no relapse after week eight and remaining in complete remission at one year. The approval introduces a B-cell-targeted therapy into a paediatric and adult nephrology setting where repeated relapses and prolonged immunosuppression can create substantial treatment burden. Field Content Article Type Approvals Drug Name Obinutuzumab Brand Name Gazyva Company Roche / Genentech Regulatory Authority U.S. Food and Drug Administration Approval Type New indication approval Indication Frequently relapsing or steroid-dependent childhood-onset idiopathic nephrotic syndrome in patients in complete remission Patient Population Adults and children aged two years and older Therapy Areas Nephrology; rare disease; paediatrics Technology/Modality Anti-CD20 monoclonal antibody Clinical Study Phase III INShore Key Result 95% of Gazyva-treated patients experienced no relapse after week eight and were in complete remission at one year, compared with 73% receiving mycophenolate mofetil Geography United States What Happened The FDA approved Gazyva to reduce relapse risk in eligible patients with childhood-onset idiopathic nephrotic syndrome. Why It Matters The approval provides a new B-cell-directed option for patients with frequently relapsing or steroid-dependent disease. Supporting Context Relapsing nephrotic syndrome can require repeated corticosteroid or immunosuppressive treatment, creating significant long-term treatment burden. Potential Impact Gazyva may help prolong remission and reduce relapse frequency in eligible patients. Key Takeaway Gazyva is now FDA approved for frequently relapsing or steroid-dependent childhood-onset idiopathic nephrotic syndrome from age two. What to Watch Treatment uptake, durability of remission and positioning relative to existing immunosuppressive strategies. Primary Source U.S. Food and Drug Administration Relevant Date 25 September 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

The FDA has expanded Camzyos approval to paediatric patients with symptomatic obstructive hypertrophic cardiomyopathy who weigh at least 30kg. Camzyos (mavacamten) is now approved to improve functional capacity and symptoms in both adults and eligible paediatric patients with obstructive hypertrophic cardiomyopathy. The expansion, supported by the Phase III SCOUT-HCM study, extends cardiac myosin inhibition into a younger patient population with this inherited heart condition. Field Content Article Type Approvals Drug Name Mavacamten Brand Name Camzyos Company Bristol Myers Squibb Regulatory Authority U.S. Food and Drug Administration Approval Type Indication expansion Indication Symptomatic obstructive hypertrophic cardiomyopathy Patient Population Adults and paediatric patients weighing at least 30kg Therapy Areas Cardiology; hypertrophic cardiomyopathy Technology/Modality Cardiac myosin inhibitor Clinical Study Phase III SCOUT-HCM Geography United States What Happened The FDA expanded Camzyos approval to eligible paediatric patients with symptomatic obstructive hypertrophic cardiomyopathy. Why It Matters The decision extends a disease-specific therapy for oHCM into a paediatric population with limited targeted treatment options. Supporting Context Bristol Myers Squibb describes Camzyos as the only FDA-approved therapy for oHCM in a paediatric population. Potential Impact The label expansion broadens access to cardiac myosin inhibition for younger patients meeting the weight and disease criteria. Key Takeaway Camzyos is now FDA approved for symptomatic oHCM in adults and eligible paediatric patients. What to Watch Paediatric uptake, guideline integration and longer-term safety and effectiveness data from younger patients. Primary Source Bristol Myers Squibb Relevant Date 30 September 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

AstraZeneca is investing $2 billion in Summit Therapeutics while launching a clinical collaboration centred on the PD-1/VEGF bispecific antibody ivonescimab. The investment gives AstraZeneca an interest equivalent to approximately 12% of Summit's outstanding common stock and establishes an initial programme combining ivonescimab with AstraZeneca's CLDN18.2 ADC sonesitatug vedotin. The collaboration creates a broader framework for testing ivonescimab alongside additional AstraZeneca oncology medicines across gastrointestinal and potentially other cancers. Field Content Article Type Deals Companies AstraZeneca; Summit Therapeutics Deal Type Strategic equity investment and clinical collaboration Investment $2 billion Equity Position Equivalent to approximately 12% of Summit Therapeutics' outstanding common stock Key Asset Ivonescimab Therapy Areas Oncology; gastrointestinal cancers Technology/Modality PD-1/VEGF bispecific antibody Initial Combination Ivonescimab plus sonesitatug vedotin Partner Asset Sonesitatug vedotin, a CLDN18.2 antibody-drug conjugate What Happened AstraZeneca agreed a $2 billion investment in Summit Therapeutics alongside a clinical collaboration around ivonescimab. Why It Matters The transaction pairs a late-stage bispecific immunotherapy platform with AstraZeneca's broad oncology pipeline and creates opportunities for multiple combination strategies. Supporting Context The first announced programme will evaluate ivonescimab with AstraZeneca's CLDN18.2 ADC in gastrointestinal cancers. Strategic Rationale AstraZeneca gains exposure to ivonescimab while Summit gains a major pharmaceutical partner for combination development. Potential Impact The partnership could expand the range of ivonescimab combinations evaluated across solid tumours. Key Takeaway AstraZeneca is investing $2 billion in Summit and building a wider oncology collaboration around ivonescimab. What to Watch Clinical trial initiation, additional combination programmes and development strategy across tumour types. Primary Source AstraZeneca Relevant Date 28 September 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

Sun Pharma has secured rights to commercialise and manufacture LIB Therapeutics' PCSK9 inhibitor lerodalcibep across markets outside the US and China. The agreement covers the EU-approved therapy, marketed as Lyrokaul, and includes upfront and milestone payments to LIB Therapeutics as well as royalties on future sales. The partnership expands Sun Pharma's cardiovascular portfolio while providing LIB Therapeutics with a commercialisation partner across a broad international territory. Field Content Alert Type Licensing agreement Companies Sun Pharmaceutical Industries; LIB Therapeutics Deal Type Exclusive licensing, commercialisation and manufacturing agreement Asset or Company Lerodalcibep (Lyrokaul) Therapy Area(s) Cardiovascular disease; hypercholesterolaemia Technology or Modality PCSK9 inhibitor Deal Value Upfront and milestone payments plus royalties; financial amounts not disclosed Development Stage Approved in the European Union Geography Markets outside the US and China What Happened Sun Pharma entered an agreement with LIB Therapeutics for the licensing, commercialisation and manufacturing of lerodalcibep outside the US and China. Why It Matters The transaction gives Sun Pharma access to an approved PCSK9-targeted cardiovascular therapy across a broad international territory. Supporting Context Lerodalcibep, marketed as Lyrokaul, has received European Union approval for the treatment of adults with primary hypercholesterolaemia and mixed dyslipidaemia. Strategic Rationale The agreement expands Sun Pharma's specialty cardiovascular portfolio while providing LIB Therapeutics with commercial and manufacturing capabilities across international markets. Potential Impact The partnership could broaden commercial access to lerodalcibep across markets covered by the agreement. Key Takeaway Sun Pharma has secured broad ex-US and ex-China rights to LIB Therapeutics' approved PCSK9 inhibitor lerodalcibep. What to Watch Commercial rollout of lerodalcibep in markets covered by the agreement and any subsequent regulatory or reimbursement developments. Primary Source Sun Pharmaceutical Industries Relevant Date 28 September 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

AstraZeneca is investing $2bn in Summit Therapeutics alongside a clinical collaboration focused on combinations involving the PD-1/VEGF bispecific antibody ivonescimab. The companies plan to evaluate ivonescimab with AstraZeneca oncology medicines, beginning with the antibody-drug conjugate sonesitatug vedotin. The transaction combines a major equity investment with expanded clinical collaboration around one of the industry's closely watched PD-1/VEGF programmes. Field Content Alert Type Strategic investment and clinical collaboration Companies AstraZeneca; Summit Therapeutics Deal Type Equity investment and clinical collaboration Asset or Company Ivonescimab Therapy Area(s) Oncology Technology or Modality PD-1/VEGF bispecific antibody Deal Value $2bn equity investment Development Stage Clinical development Geography Global collaboration What Happened AstraZeneca announced a $2bn equity investment in Summit Therapeutics alongside a clinical collaboration to evaluate combinations involving ivonescimab and AstraZeneca oncology medicines. Why It Matters The agreement expands AstraZeneca's exposure to the emerging PD-1/VEGF bispecific field while creating opportunities to evaluate ivonescimab alongside assets from its established oncology portfolio. Supporting Context The collaboration is expected to begin by evaluating ivonescimab in combination with AstraZeneca's antibody-drug conjugate sonesitatug vedotin. Strategic Rationale AstraZeneca gains strategic exposure to Summit and an opportunity to explore combinations between ivonescimab and its own oncology pipeline. Potential Impact The collaboration could generate new combination regimens involving PD-1/VEGF inhibition and AstraZeneca oncology therapies if clinical studies support their use. Key Takeaway AstraZeneca is making a $2bn strategic investment in Summit while expanding clinical work around ivonescimab combination therapies. What to Watch Initiation and results of combination studies involving ivonescimab and AstraZeneca oncology assets. Primary Source AstraZeneca Relevant Date 28 September 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

Merck has secured worldwide rights to SciBrunch Therapeutics' preclinical KRAS G12D inhibitor SPR2015 in an oncology licensing agreement worth up to $2.13bn. SciBrunch will receive $400m upfront, with additional development, regulatory and commercial milestones potentially taking aggregate consideration to $2.13bn. The agreement gives Merck responsibility for the development, manufacturing and commercialisation of SPR2015 worldwide. Field Content Alert Type Licensing agreement Companies Merck; SciBrunch Therapeutics Deal Type Exclusive global licence Asset or Company SPR2015 Therapy Area(s) Oncology Technology or Modality Oral KRAS G12D ON inhibitor Deal Value $400m upfront; aggregate potential consideration of up to $2.13bn Development Stage Preclinical Geography Worldwide What Happened Merck entered an exclusive global licence agreement with SciBrunch Therapeutics for SPR2015, an investigational oral KRAS G12D ON inhibitor. Why It Matters KRAS G12D is an important oncology target across multiple tumour types, and the agreement expands Merck's pipeline of investigational targeted cancer therapies. Supporting Context SciBrunch will receive $400m upfront and is eligible for additional development, regulatory and commercial milestone payments that could bring aggregate consideration to $2.13bn. Strategic Rationale The transaction gives Merck control of a preclinical targeted therapy designed to inhibit the active state of KRAS G12D. Potential Impact SPR2015 could add another approach to targeting KRAS-driven cancers if it progresses successfully through clinical development. Key Takeaway Merck is committing $400m upfront for worldwide rights to SPR2015, with the oncology licensing agreement potentially reaching $2.13bn. What to Watch Progression of SPR2015 from preclinical development into human clinical trials. Primary Source Merck Relevant Date 28 September 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

Novo Nordisk has secured rights outside Greater China to Hengrui Pharma's once-weekly oral GLP-1/GIP dual receptor agonist HRS-1596 in a deal worth up to $2.6bn. Hengrui will receive $300m upfront, with total potential consideration of up to $2.6bn plus royalties as Novo Nordisk adds the phase 1-ready candidate to its obesity and metabolic disease pipeline. The agreement gives Novo Nordisk global rights outside Greater China to develop, manufacture and commercialise HRS-1596. Field Content Alert Type Licensing agreement Companies Novo Nordisk; Hengrui Pharma Deal Type Exclusive licence Asset or Company HRS-1596 Therapy Area(s) Obesity and metabolic disease Technology or Modality Once-weekly oral GLP-1/GIP dual receptor agonist Deal Value $300m upfront; total potential consideration of up to $2.6bn plus royalties Development Stage Phase 1-ready Geography Global rights outside Greater China What Happened Novo Nordisk entered an exclusive licence agreement with Hengrui Pharma for HRS-1596, a once-weekly oral GLP-1/GIP dual receptor agonist. Why It Matters The agreement adds another oral incretin-based candidate to Novo Nordisk's metabolic disease pipeline as competition continues across next-generation obesity treatments. Supporting Context Hengrui will receive $300m upfront and is eligible for additional development, regulatory and commercial milestone payments, taking potential total consideration to up to $2.6bn, as well as royalties. Strategic Rationale Novo Nordisk gains access to a differentiated once-weekly oral GLP-1/GIP programme that complements its existing obesity and metabolic disease portfolio. Potential Impact Successful development could broaden the range of oral incretin-based treatment options available within the competitive obesity market. Key Takeaway Novo Nordisk is expanding its next-generation obesity pipeline through a potentially $2.6bn licensing agreement for Hengrui's once-weekly oral GLP-1/GIP candidate. What to Watch Clinical development of HRS-1596 and progression beyond its initial Phase I programme. Primary Source Novo Nordisk Relevant Date 29 September 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

Merck has secured exclusive worldwide rights to SciBrunch Therapeutics' preclinical KRAS G12D inhibitor SPR2015 in an oncology licensing transaction worth up to $2.13 billion. SciBrunch will receive $400 million upfront, with additional development, commercial and other milestone payments potentially taking the total transaction value to $2.13 billion. The agreement gives Merck a preclinical oral KRAS G12D (ON) inhibitor targeting one of the most important oncogenic mutations across multiple tumour types. Field Content Article Type Deals Companies Merck; SciBrunch Therapeutics Deal Type Exclusive global licensing agreement Asset SPR2015 Therapy Areas Oncology Technology/Modality Oral KRAS G12D (ON) inhibitor Development Stage Preclinical Upfront Payment $400 million Potential Deal Value Up to $2.13 billion Geography Worldwide What Happened Merck secured exclusive worldwide rights to SciBrunch Therapeutics' investigational oral KRAS G12D (ON) inhibitor SPR2015. Why It Matters The transaction adds a targeted oncology programme directed at KRAS G12D, a major oncogenic driver across several difficult-to-treat cancers. Supporting Context SPR2015 is a preclinical small-molecule programme designed to inhibit the active ON state of KRAS G12D. Strategic Rationale Merck gains a potentially differentiated KRAS-targeted asset for its oncology pipeline while SciBrunch receives substantial upfront funding and downstream milestone opportunities. Potential Impact Successful development could expand targeted treatment options for patients with KRAS G12D-mutated cancers. Key Takeaway Merck is paying $400 million upfront for SPR2015 in a licensing transaction worth up to $2.13 billion. What to Watch IND-enabling development, entry into clinical trials and initial evidence of activity across KRAS G12D-mutated tumours. Primary Source Merck Relevant Date 28 September 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

The FDA has approved Emcitate as the first treatment for MCT8 deficiency, providing a therapy for the peripheral thyrotoxicosis associated with this ultra-rare genetic disorder. Emcitate (tiratricol) is approved for adults and paediatric patients with MCT8 deficiency, also known as Allan-Herndon-Dudley syndrome. The first-in-disease approval provides a treatment designed to act without relying on the defective MCT8 transporter responsible for the disorder. Field Content Article Type Approvals Drug Name Tiratricol Brand Name Emcitate Regulatory Authority U.S. Food and Drug Administration Approval Type First FDA-approved treatment for MCT8 deficiency Indication Peripheral thyrotoxicosis in adults and paediatric patients with MCT8 deficiency Therapy Areas Rare disease; endocrinology; neurology Disease MCT8 deficiency / Allan-Herndon-Dudley syndrome Technology/Modality Thyroid hormone analogue Geography United States What Happened The FDA approved Emcitate for peripheral thyrotoxicosis in adults and paediatric patients with MCT8 deficiency. Why It Matters Emcitate is the first FDA-approved treatment for MCT8 deficiency, addressing an ultra-rare genetic disorder with no previously approved therapy. Supporting Context MCT8 deficiency results from defects in the MCT8 thyroid hormone transporter and is also known as Allan-Herndon-Dudley syndrome. Potential Impact The approval establishes the first US pharmacological treatment option for patients with MCT8 deficiency. Key Takeaway Emcitate becomes the first FDA-approved treatment for MCT8 deficiency. What to Watch US launch, patient access and longer-term evidence from treatment in adults and children. Primary Source U.S. Food and Drug Administration Relevant Date 28 September 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com